Suppr超能文献

HLA Ⅱ类四聚体揭示了组织特异性调节性 T 细胞,这些细胞可抑制乳腺癌患者的 T 细胞应答。

HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.

机构信息

German Cancer Research Center and National Center for Tumor Diseases; Heidelberg, Germany.

出版信息

Oncoimmunology. 2013 Jun 1;2(6):e24962. doi: 10.4161/onci.24962. Epub 2013 May 15.

Abstract

Regulatory T cells (Tregs) play an important role in controlling antitumor T-cell responses and hence represent a considerable obstacle for cancer immunotherapy. The abundance of specific Treg populations in cancer patients has been poorly analyzed so far. Here, we demonstrate that in breast cancer patients, Tregs often control spontaneous effector memory T-cell responses against mammaglobin, a common breast tissue-associated antigen that is overexpressed by breast carcinoma. Using functional assays, we identified a HLA-DRB104:01- and HLA-DRB107:01-restricted epitope of mammaglobin (mam) that was frequently recognized by Tregs isolated from breast cancer patients. Using mam-labeled HLA Class II tetramers, we quantified mammaglobin-specific Tregs and CD4 conventional T (Tcon) cells in breast carcinoma patients as well as in healthy individuals. Both mammaglobin-specific Tregs and Tcon cells were expanded in breast cancer patients, each constituting approximately 0.2% of their respective cell subpopulations. Conversely, mammaglobin-specific Tregs and CD4 Tcon cells were rare in healthy individuals (0.07%). Thus, we provide here for the first time evidence supporting the expansion of breast tissue-specific Tregs and CD4 Tcon cells in breast cancer patients. In addition, we substantiate the potential implications of breast tissue-specific Tregs in the suppression of antitumor immune responses in breast cancer patients. The HLA Class II tetramers used in this study may constitute a valuable tool to elucidate the role of antigen-specific Tregs in breast cancer immunity and to monitor breast cancer-specific CD4 T cells.

摘要

调节性 T 细胞(Tregs)在控制抗肿瘤 T 细胞反应方面发挥着重要作用,因此代表了癌症免疫治疗的一个重大障碍。迄今为止,癌症患者中特定 Treg 群体的丰度尚未得到充分分析。在这里,我们证明在乳腺癌患者中,Tregs 通常控制针对乳球蛋白的自发效应记忆 T 细胞反应,乳球蛋白是一种常见的乳腺组织相关抗原,在乳腺癌中过表达。使用功能测定,我们鉴定了乳球蛋白(mam)的 HLA-DRB104:01-和 HLA-DRB107:01 限制性表位,该表位经常被从乳腺癌患者中分离的 Tregs 识别。使用 mam 标记的 HLA Ⅱ类四聚体,我们在乳腺癌患者以及健康个体中定量了乳球蛋白特异性 Tregs 和 CD4 常规 T(Tcon)细胞。在乳腺癌患者中,乳球蛋白特异性 Tregs 和 Tcon 细胞均扩增,每个细胞亚群约占 0.2%。相反,乳球蛋白特异性 Tregs 和 CD4 Tcon 细胞在健康个体中很少见(0.07%)。因此,我们在这里首次提供了支持乳腺癌患者中乳腺组织特异性 Tregs 和 CD4 Tcon 细胞扩增的证据。此外,我们证实了乳腺组织特异性 Tregs 在抑制乳腺癌患者抗肿瘤免疫反应中的潜在意义。本研究中使用的 HLA Ⅱ类四聚体可能构成阐明乳腺癌免疫中抗原特异性 Tregs 作用以及监测乳腺癌特异性 CD4 T 细胞的有价值工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/894c/3716760/781dded7a106/onci-2-e24962-g1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验